NRD
LMAT icon

Nebula Research & Development’s LeMaitre Vascular LMAT Stock Holding History

Nebula Research & Development’s Portfolio LMAT Stock Details LMAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,180
Closed -$430K – 491
2025
Q2 		$430K Sell
5,180
-3,875
-43% -$324K 0.04% 680
2025
Q1 		$760K Buy
9,055
+586
+7% +$54.5K 0.07% 465
2024
Q4 		$780K Buy
8,469
+5,206
+160% +$501K 0.09% 382
2024
Q3 		$303K Sell
3,263
-660
-17% -$57.2K 0.04% 707
2024
Q2 		$323K Sell
3,923
-2,841
-42% -$209K 0.05% 587
2024
Q1 		$449K Buy
6,764
+492
+8% +$30.4K 0.1% 394
2023
Q4 		$356K Buy
+6,272
New +$329K 0.11% 376

Other funds holding LMAT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return
GCM
Geneva Capital Management Milwaukee, Wisconsin $4.71B AUM 6.32% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nebula Research & Development's LMAT Position: Q3 2025 in Review

Nebula Research & Development sold out of LeMaitre Vascular (LMAT) in Q3 2025, closing a stake of 5,180 shares — an estimated $430K sold.

Nebula Research & Development first reported a position in LMAT in Q4 2023 and held it in 7 quarters. The position peaked at $780K in Q4 2024. 297 funds tracked by Wall St. Rank hold LMAT as of Q3 2025.

  • Nebula Research & Development reported no remaining LeMaitre Vascular position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 5,180 LeMaitre Vascular shares in Q3 2025, an estimated $430K.
  • Nebula Research & Development first reported a position in LeMaitre Vascular in Q4 2023 and held it in 7 quarters.
  • Nebula Research & Development's LeMaitre Vascular position peaked at $780K in Q4 2024.
  • 297 funds tracked by Wall St. Rank held LeMaitre Vascular as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.